. 2019 Apr 20;10(2):90–100. doi: 10.14740/wjon1193

Table 2. Baseline Characteristics, Treatment, and Laboratory Data According to RMH score (N = 76).

N	RMH score		P
N	Low (N = 44)	High (N = 32)	P
Backgrounds
Sex (N)
Male/female	31/13	18/14	0.23^a
Age (years)
Median (IQR)	69.5 (63 - 73)	70.5 (61.25 - 75)	0.63^b
Smoking status (N)
NS/Ex, CS	7/37	9/23	0.26^a
BMI
Median (IQR)	22.0 (20.5 - 23.8)	23.1 (19.3 - 26.5)	0.20^b
≥ 18.5/< 18.5 (N)	36/8	26/6	1.00^a
Histology (N)
Non-SQ/SQ	30/14	28/4	0.06^a
EGFR mutation (N)
(-) or NA/(+)	35/9	30/2	0.11^a
PD-L1 status (N)
≥ 50%/1-49%/< 1%/NA	9/10/3/22	5/5/5/17	0.57^a
ECOG-PS (N)
0-1/2/3	33/9/2	21/8/3	0.58^a
Metastatic sites (N)
< 3/≥ 3	28/16	7/25	< 0.01^a
Treatment
ICI regimen (N)			0.77^a
Nivolumab	32	26
Pembrolizumab	9	4
Atezolizumab	3	2
Previous treatment (N)
Anti-angiogenic drug	18	18	0.25^a
EGFR-TKIs	11	4	0.25^a
Radiotherapy	11	8	1.00^a
Further line treatment (N)	24	16	0.82^a
ICI efficacy
ORR (%) (95% CI)	20.5 (9.8 - 35.3)	6.2 (0.8 - 20.8)	0.11^a
DCR (%) (95% CI)	40.9 (26.3 - 56.8)	25.0 (11.5 - 43.4)	0.15^a
Laboratory data
NLR
Median (IQR)	2.92 (2.02 - 3.99)	3.75 (2.30 - 5.47)	0.14^b
> 6 (N)	4	7	0.19^a
LDH (U/L)
Median (IQR)	197 (179 - 219)	304 (233.8 - 344)	< 0.01^b
> ULN (N)	9	26	< 0.01^a
Albumin (g/dL)
Median (IQR)	3.8 (3.5 - 4.0)	3.2 (2.9 - 3.6)	< 0.01^b
< 3.5 g/dL (N)	8	22	< 0.01^a

^aFisher’s exact test, ^bMann-Whitney U test. BMI: body mass index; CI: confidence interval; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; EGFR: epidermal growth factor receptor; Ex: ex-smoker; IQR: interquartile range; ICI: immune-checkpoint inhibitor; LDH: lactate dehydrogenase; NA: not assessed; NLR: neutrophil-to-lymphocyte ratio; NS: non-smoker; ORR: overall response rate; RMH score: Royal Marsden Hospital prognostic score; SQ; squamous cell carcinoma; TKI: tyrosine kinase inhibitor; ULN: upper limit of normal.